Literature DB >> 6431750

A consecutive series of 30 malignant schwannomas. Survival in relation to clinico-pathological parameters and treatment.

M Bojsen-Møller, O Myhre-Jensen.   

Abstract

Thirty malignant schwannomas from an 18-year period were studied, and the patients were divided into 3 groups: one with Recklinghausen's disease, one with tumours related to nerves but without Recklinghausen's disease and finally one with a histopathology best compatible with malignant schwannoma. On all tumours a histopathological grading was performed, and all except two were found to be high-grade malignant. The follow-up is from 2 to 20 years, and only two of the living patients have not yet been followed for 5 years. One patient has been lost during the follow-up period. In the remaining 27 patients the 5-year survival is 48%. The factors essential to the prognosis are: the tumour localization, size, grade of malignancy and radical surgical treatment. The coexistence of Recklinghausen's disease and malignant schwannoma seems not in itself to give a worse prognosis; it is rather the large tumours and unfavourable localizations in this group of patients that shortens the survival, the 5-year survival being 37.5%.

Entities:  

Mesh:

Year:  1984        PMID: 6431750

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Immunol Scand A        ISSN: 0108-0164


  8 in total

1.  Epithelioid malignant schwannoma. A study of 14 cases.

Authors:  P Lodding; L G Kindblom; L Angervall
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

2.  Intraosseous nerve sheath tumors in the jaws.

Authors:  Zhongmin Che; Woong Nam; Won-Se Park; Hyung-Jun Kim; In-Ho Cha; Hyun-Sil Kim; Jong-In Yook; Jin Kim; Sang-Hwy Lee
Journal:  Yonsei Med J       Date:  2006-04-30       Impact factor: 2.759

Review 3.  Juxta-adrenal malignant schwannoma.

Authors:  M A Fabbro; L Costa; S D'Agostino; L Musi; G P Belloli
Journal:  Pediatr Surg Int       Date:  1997-09       Impact factor: 1.827

4.  [A resected case of malignant peripheral nerve sheath tumor (MPNST) necessary to distinguish from Askin tumor].

Authors:  M Odaka; S Yamazaki; T Akiba; R Mizuno; T Harada; Y Yamazaki
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-11

5.  Malignant triton tumour in the cerebellopontine angle. Report of a case.

Authors:  P V Best
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

Review 6.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Authors:  Matthias Kolberg; Maren Høland; Trude H Agesen; Helge R Brekke; Knut Liestøl; Kirsten S Hall; Fredrik Mertens; Piero Picci; Sigbjørn Smeland; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

7.  Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients.

Authors:  Elizabeth Shurell; Linh M Tran; Jonathan Nakashima; Kathleen B Smith; Brenna M Tam; Yunfeng Li; Sarah M Dry; Noah Federman; William D Tap; Hong Wu; Fritz C Eilber
Journal:  BMC Cancer       Date:  2014-11-15       Impact factor: 4.430

8.  Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours.

Authors:  D E Porter; V Prasad; L Foster; G F Dall; R Birch; R J Grimer
Journal:  Sarcoma       Date:  2009-04-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.